Isoniazid

• 

  Subject Areas on Research

  • A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. 
  • Antepartum or postpartum isoniazid treatment of latent tuberculosis infection. 
  • Central nervous system infection and cutaneous lymphadenitis due to Mycobacterium kansasii in an immunocompetent patient. 
  • Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. 
  • Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™. 
  • Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. 
  • Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. 
  • Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. 
  • Detection of hydrazine, methylhydrazine and isoniazid by capillary electrophoresis with a 4-pyridyl hydroquinone self-assembled microdisk platinum electrode. 
  • Do clinical decision-support reminders for medical providers improve isoniazid preventative therapy prescription rates among HIV-positive adults? Study protocol for a randomized controlled trial. 
  • Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group. 
  • Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial. 
  • Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. 
  • Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? 
  • Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. 
  • Isoniazid preventive therapy in medium-incidence settings: the price is right. 
  • Letter: Treatment of meningitis and encephalitis. 
  • Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis. 
  • Metabolic effects of isonicotinic acid hydrazid (INH) toxicity in Saccharomyces cerevislae. 
  • Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. 
  • Monitored isoniazid prophylaxis for low-risk tuberculin reactors. 
  • Neonatal tuberculosis: neonatal intensive care unit considerations in the United States. 
  • Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. 
  • Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. 
  • Regulation of rat hepatic cytochrome P450IIE1 in primary monolayer hepatocyte culture. 
  • Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. 
  • Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania. 
  • Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. 
  • Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. 
  • Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis. 
  • The action of oxygen and oxygen at high pressure on inhibitory transmission. 
  • The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. 
  • The penetration of dapsone, rifampicin, isoniazid and pyrazinamide into peripheral nerves. 
  • Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. 
  • Three months of rifapentine and isoniazid for latent tuberculosis infection. 
  • Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. 
  • Who is taking their tablets? 
  • [Editorial: New problems in the diagnosis and classification of silicosis and its prevention]